3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
10
Withdrawn
2
Not yet recruiting
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
36
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Burkitt Lymphoma
7
Neoplasms
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
6
Leukemia
6
Lymphoma, B-Cell
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Recurrence
3
Neoplasm Metastasis
3
Lymphoma, T-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Hodgkin Disease
3
Waldenstrom Macroglobulinemia
2
Pain
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Neoplasms
2
Hematologic Diseases
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumours
1
Sezary Syndrome
1
Interventions
Filgrastim
8
Cyclophosphamide
8
Cyclosporine
7
fludarabine phosphate
6
Antilymphocyte Serum
6
Rituximab
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Methotrexate
5
Cord Blood Stem Cell Transplantation
5
Etoposide
4
Busulfan
4
Whole-Body Irradiation
3
Methylprednisolone
3
Melphalan
3
Vincristine
2
Tacrolimus
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Doxorubicin
2
Cytarabine
2
Carboplatin
2
Amplified Fragment Length Polymorphism Analysis
2
venetoclax
1
pegfilgrastim
1
obatoclax
1
ibritumomab tiuxetan
1
fludarabine
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Dendritic Cell Sarcoma, Interdigitating
×
Prednisone
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts